188 related articles for article (PubMed ID: 26521911)
1. Unilateral Capecitabine-related Hand-foot Syndrome.
Matsuda S; Koketsu H; Hayakawa M; Nagata N
Intern Med; 2015; 54(21):2779. PubMed ID: 26521911
[No Abstract] [Full Text] [Related]
2. [Therapy traces on hands and feet in a patient with colon cancer].
Stiefelhagen P
MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():9. PubMed ID: 22916416
[No Abstract] [Full Text] [Related]
3. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
[TBL] [Abstract][Full Text] [Related]
4. Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
Chan HY; Ng CM; Tiu SC; Chan AO; Shek CC
Hong Kong Med J; 2012 Dec; 18(6):526-9. PubMed ID: 23223655
[TBL] [Abstract][Full Text] [Related]
5. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
[TBL] [Abstract][Full Text] [Related]
6. Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine.
Ljubojevic Hadzavdic S; Stulhofer Buzina D; Murtezani I; Skerlev M
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e304-e306. PubMed ID: 27987319
[No Abstract] [Full Text] [Related]
7. [Breast cancer and the hand-foot syndrome].
Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
[TBL] [Abstract][Full Text] [Related]
8. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy.
Li Z; Jiang N; Xu Y
Australas J Dermatol; 2016 Feb; 57(1):e14-6. PubMed ID: 25495707
[TBL] [Abstract][Full Text] [Related]
9. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
10. Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Matsuda K; Namiki T; Ueno M; Hashimoto T; Hanafusa T; Yokozeki H
Eur J Dermatol; 2017 Jun; 27(3):323-325. PubMed ID: 28414195
[No Abstract] [Full Text] [Related]
11. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Huang HY; Jiang ZF; Wang T; Zhang SH; Bian L; Cao Y; Wu SK; Song ST
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):850-3. PubMed ID: 22335952
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Schüll B; Scheithauer W; Kornek GV
Onkologie; 2003 Dec; 26(6):578-80. PubMed ID: 14709934
[TBL] [Abstract][Full Text] [Related]
13. Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
Zhao J; Zhang X; Cui X; Wang D; Zhang B; Ban L
Oncol Res; 2020 Feb; 28(1):103-106. PubMed ID: 31558182
[TBL] [Abstract][Full Text] [Related]
14. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Chao YL; Anders CK
Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
[No Abstract] [Full Text] [Related]
15. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
16. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Glen H; Cassidy J
Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
[TBL] [Abstract][Full Text] [Related]
17. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
[No Abstract] [Full Text] [Related]
18. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
[TBL] [Abstract][Full Text] [Related]
19. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
[TBL] [Abstract][Full Text] [Related]
20. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
